Merck Aims To Be India’s Largest Vaccine Maker
This article was originally published in PharmAsia News
Executive Summary
Merck says it expects to be the largest drug maker producing vaccines in India within five years. The firm's intent is to develop vaccines for treating cancer, diarrhea and shingles, three primary diseases in India. The government has a national immunization program that Merck seeks to be associated with in its vaccine production, but plans to associate with individual states as well. The head of MSD Pharma, Merck's India arm, said the firm also plans to launch its other drugs at a rate faster than the usual 17 to 20 years after launching in the United States or Europe, perhaps even simultaneously. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.